ArticleBMC pharmacology & toxicology2026
Thyroid hormone changes after tumor necrosis factor inhibitor therapy in euthyroid patients with rheumatic diseases.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimTumor necrosis factor-alpha (TNF-α) plays a central role in chronic inflammatory diseases. Anti-TNF agents are widely used in rheumatological conditions; however, their association with thyroid hormone parameters in patients without pre-existing thyroid disease remains incompletely understood. This study aimed to evaluate changes in thyroid hormone profiles during anti-TNF therapy in euthyroid patients with rheumatic diseases.
methodsIn this retrospective study, 98 patients diagnosed with rheumatoid arthritis, ankylosing spondylitis, or Behçet’s disease without known thyroid disease were evaluated. Thyroid function tests, including thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), and free thyroxine (fT4), anti-thyroid peroxidase (anti-TPO) antibodies, inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), and metabolic parameters were assessed at baseline and after 3 and 6 months of anti-TNF therapy.
resultsAnti-TNF therapy was associated with significant reductions in inflammatory markers (CRP and ESR, p < 0.01). A modest decrease in fasting glucose levels and an increase in high-density lipoprotein cholesterol (HDL-C) were observed during follow-up (p = 0.024 and p = 0.044, respectively). TSH and fT4 levels remained stable over time, whereas a gradual increase in fT3 levels was observed (p < 0.01). No significant changes were detected in anti-TPO antibody levels.
conclusionsAmong euthyroid patients with rheumatic diseases, predominantly rheumatoid arthritis and ankylosing spondylitis, anti-TNF therapy was associated with stable thyroid function parameters. The observed increase in fT3 levels may reflect reduced inflammatory burden rather than direct thyroidal effects. These findings support the thyroid safety of anti-TNF agents while highlighting potential links between inflammation control and peripheral thyroid hormone conversion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.